16099-65-3

Basic information

• Product Name: 2-Imidazolidinethione, 1-phenyl-
• CAS NO: 16099-65-3
• Molecular Formula: C9H10N2S
• Molecular Weight: 178.258
• Mol File: 16099-65-3.mol
• Article Data: 8

Chemical Properties

• CAS DataBase Reference: 2-Imidazolidinethione, 1-phenyl-(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Imidazolidinethione, 1-phenyl-(16099-65-3)
• EPA Substance Registry System: 2-Imidazolidinethione, 1-phenyl-(16099-65-3)

Safety Data

• Hazardous Substances Data: 16099-65-3(Hazardous Substances Data)

Upstream product

• 1664-40-0 N-(2-aminoethyl)benzeneamine 
• 6160-65-2 1,1'-Thiocarbonyldiimidazole 
• 103-72-0 phenyl isothiocyanate 
• 141-43-5 ethanolamine 
• 333-20-0 potassium thioacyanate 
• 75-15-0 carbon disulfide 

Downstream Products

• 1848-78-8 phenyl-(1-phenyl-4,5-dihydro-1H-imidazol-2-yl)-amine 
• 1127329-52-5 tert-butyl [(6-(7-(2-fluoro-4-(3-phenyl-2-thioxoimidazolidine-1-carboxamido)phenoxy)thieno[3,2-b]pyridin-2-yl)pyridin-3-yl)methyl](2-methoxyethyl)carbamate 
• 1020536-36-0 3-phenyl-N-(3-(6-(pyrrolidine-1-carboxamido)pyridin-3-yloxy)phenyl)-2-thioxoimidazolidine-1-carboxamide 
• 150928-59-9 2,7-Diphenyl-5H,6H,7H-imidazole[2,1-b]-1,4-thiazolium-3-thiolate 
• 67389-58-6 2-(methylthio)-1-phenyl-4,5-dihydro-1H-imidazole 

Relevant articles and documents

Precursor reaction kinetics control compositional grading and size of CdSe1-: XSx nanocrystal heterostructures

We report a method to control the composition and microstructure of CdSe1-xSx nanocrystals by the simultaneous injection of sulfide and selenide precursors into a solution of cadmium oleate and oleic acid at 240 °C. Pairs of substituted thio- and selenoureas were selected from a library of compounds with conversion reaction reactivity exponents (kE) spanning 1.3 × 10-5 s-1 to 2.0 × 10-1 s-1. Depending on the relative reactivity (kSe/kS), core/shell and alloyed architectures were obtained. Growth of a thick outer CdS shell using a syringe pump method provides gram quantities of brightly photoluminescent quantum dots (PLQY = 67 to 90%) in a single reaction vessel. Kinetics simulations predict that relative precursor reactivity ratios of less than 10 result in alloyed compositions, while larger reactivity differences lead to abrupt interfaces. CdSe1-xSx alloys (kSe/kS = 2.4) display two longitudinal optical phonon modes with composition dependent frequencies characteristic of the alloy microstructure. When one precursor is more reactive than the other, its conversion reactivity and mole fraction control the number of nuclei, the final nanocrystal size at full conversion, and the elemental composition. The utility of controlled reactivity for adjusting alloy microstructure is discussed.

Synthesis of Isothiocyanates and Unsymmetrical Thioureas with the Bench-Stable Solid Reagent (Me4N)SCF3

A highly efficient, selective, and rapid transformation of primary amines and diamines to isothiocyanates and cyclic thioureas is disclosed. As opposed to established approaches that employ toxic or volatile electrophilic liquids and require reaction control (i.e., slow addition, cooling), this protocol utilizes the bench-stable, solid reagent (Me4N)SCF3 at room temperature. The method is characterized by operational simplicity, high speed, efficiency, high functional group tolerance, and late-stage applicability. The byproducts are solids, allowing isolation of the target compounds by filtration.

INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY

The invention relates to compounds of Formula (I) and their use for inhibiting protein tyrosine kinase activity In Formula (I), the group M is thieno[3,2,b]pyridinyl as shown, and the group D is a ring or ring system, and the groups Z, Ar, and G are as defined herein The invention relates particularly to compounds that inhibit the protein tyrosine kinase activity of growth factor receptors, resulting in the inhibition of receptor signalling, for example, the inhibition of VEGF receptor signalling and HGF receptor signalling The invention also provides compositions and methods for treating cell proliferative diseases and conditions, such as cancer, and for treating ophthalmic diseases, including age-related macular degeneration (AMD) and diabetic retinopathy (DR)